GlassScriptPhysician profile
Zachary Simons
NPI 1215680632
$10,137.46
in general payments reported to CMS, 2019-2025
21 companies · $4,343 in 2025
The $4,343 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,107 · 2023: $2,320 · 2024: $2,367 · 2025: $4,343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,296 · Travel and Lodging: $2,562 · Education: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,296.21 |
| Travel and Lodging | $2,562.00 |
| Education | $171.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $4,257.30 | 2025 | |
| Lumenis Be INC | $1,457.25 | 2024 | M22 |
| Abbvie INC. | $987.65 | 2022-2024 | |
| Dermavant Sciences, INC. | $695.52 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $414.65 | 2022-2024 | Ilumya |
| Regeneron Healthcare Solutions, INC. | $364.14 | 2022-2024 | Dupixent |
| Novartis Pharmaceuticals Corporation | $288.51 | 2023-2024 | |
| Lilly USA, LLC | $264.36 | 2022-2024 | Taltz, Olumiant |
| Incyte Corporation | $253.74 | 2022-2023 | Opzelura |
| Arcutis Biotherapeutics, INC. | $213.28 | 2023 | |
| Janssen Biotech, INC. | $196.11 | 2023 | Tremfya |
| Pfizer INC. | $165.35 | 2022-2024 | |
| Janssen Scientific Affairs, LLC | $124.36 | 2022 | |
| Genzyme Corporation | $100.79 | 2023-2024 | |
| Smith+Nephew, INC. | $98.73 | 2024-2025 | Allevyn Heel 10.5cm X 13.5cm Ctn 5, Acticoat 4" X 4", Allevyn Life L 15.4x15.4 Ctn10 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $67.20 | 2023 | Adbry |
| Ucb, INC. | $62.59 | 2022-2024 | Cimzia, Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $58.04 | 2022-2024 | Sotyktu |
| Solventum Corporation | $27.79 | 2024 | Prevena, V.A.C. Veraflo Cleanse Choice, V.A.C.Ulta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.12 | 2024 | Spevigo |
| Neurocrine Biosciences, INC. | $18.98 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zachary Simons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.